已核实 DOI 相关产品: 40

Orchestrating macrophage-tubular crosstalk with antioxidant nanotherapeutics to treat acute kidney injury via metabolic reprogramming

Journal 2026 · IF 12.5 · 发表于 2026 年 2 月 26 日
作者: Liya Wang,Zhuyun Zhang,Yajun Fu,Shaoyong Zhuang,Baihai Su,Xing Zhao
阅读全文 在 PubMed 查看

摘要

Acute kidney injury (AKI) affects approximately 15% of hospitalized patients globally, with significant morbidity and mortality largely attributed to disrupted immuno-parenchymal crosstalk that intensifies tissue damage. Conventional treatments predominantly manage symptoms rather than fundamentally addressing the critical interactions between immune cells and renal parenchymal cells essential for effective kidney repair. Recent advances suggest that immuno-parenchymal crosstalk can significantly influence epigenetic landscapes within these cells, presenting a novel therapeutic target for renal diseases. This study introduces an innovative antioxidant nanotherapy, formulated through a co-deposition modification strategy employing MXene, polydopamine (PDA), and hyaluronic acid (HA). The developed nanotherapeutics specifically targets CD44-expressing inflammatory immune cells, thereby substantially enhancing immuno-parenchymal crosstalk, optimizing cellular metabolism, reducing apoptosis in renal tubular cells, and correlating with improved renal outcomes. Our findings demonstrate that targeting immuno-parenchymal crosstalk with antioxidant nanotherapeutics effectively optimize epigenetic reprogramming in renal tubular cells. By strategically targeting and modulating these pivotal cellular interactions, this research marks a significant advance in AKI treatment, advocating a shift towards more targeted and effective therapeutic approaches in renal medicine.

本研究中使用的阿拉丁产品

40 款产品在本文中被引用